This listing of claims will replace all other versions and listings of claims in the application:

Claims 1-9 (Canceled)

- 10. (Currently Amended) A molecule capable of binding a plurality of antigens, the molecular comprising: [An] an isolated molecule containing two antigen binding sites and two complementary determining segments, [both] the two antigen binding sites positioned at opposite ends of the molecule [and the two complementary determining segments positioned at opposite ends of the molecule], the molecule further consisting of:
- a) a purified first moiety containing a first antigen binding region bound to a first antigen non-binding region via a peptide linker; [and]
- b) a purified second moiety containing a second antigen-binding region bound to a second antigen-non-binding region via a peptide linker, whereby the moieties are engineered so that the first moiety is rotated about 180 degrees compared to the second moiety [as to be juxtaposed to each other in a counterpoised configuration], wherein the first moiety and second moiety are derived from the same gene, and wherein the first moiety and the second moiety are light chain variable domains; and
- c) a hydrophobic residue situated intermediate the first moiety and second moiety to confer affinity between the first moiety and second moiety.

11. (Canceled)

- 12. (previously amended) The molecule as recited in claim 10 wherein the first antigen-binding region and second antigen-binding region are identical.
- 13. (original) The molecule as recited in claim 10 wherein the first moiety is covalently attached to the second moiety.
- 14. (original) The molecule as recited in claim 10 wherein the molecule has a weight of between 20,000 and 30,000 daltons.

In re STEVENS et al. (S.N. 09/368,989) Response to Nov. 17, 2004 Notice of Non-Compliance Page -3-

15-20 (Canceled)

21. (previously added) The molecule as recited in claim 10 wherein each antigen binding site comprises a complementary region and a framework region of a variable light chain protein.

22-38 (Canceled)